Cargando…

Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21)

p53 is frequently wild type (wt) in diffuse large B-cell lymphoma (DLBCL) associated with t(14;18)(q32;q21) that overexpresses BCL2. Nutlin-3a is a small molecule that activates the p53 pathway by disrupting p53–MDM2 interaction. We show that nutlin-3a activates p53 in DLBCL cells associated with t(...

Descripción completa

Detalles Bibliográficos
Autores principales:	Drakos, E, Singh, R R, Rassidakis, G Z, Schlette, E, Li, J, Claret, F X, Ford, R J, Vega, F, Medeiros, L J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094765/ https://www.ncbi.nlm.nih.gov/pubmed/21394100 http://dx.doi.org/10.1038/leu.2011.28

Ejemplares similares

Primary follicular lymphoma of the epididymis positive for t(14;18)(q32;q21)/IGH-BCL2 and negative for BCL2 protein expression: a case report
por: Tralongo, Vincenzo, et al.
Publicado: (2012)

Chronic Lymphocytic Leukemia with t(14;18)(q32;q21) As a Sole Cytogenetic Abnormality
por: Elyamany, Ghaleb, et al.
Publicado: (2014)

Immunophenotypic features and t(14;18) (q32;q21) translocation of Chinese follicular lymphomas helps to distinguish subgroups
por: Zhang, Fen, et al.
Publicado: (2013)

t(14;18)(q32;q21) in chronic lymphocytic leukemia patients: Report of two cases and a literature review
por: Chen, Weifeng, et al.
Publicado: (2016)

Interruption of p53-MDM2 Interaction by Nutlin-3a in Human Lymphoma Cell Models Initiates a Cell-Dependent Global Effect on Transcriptome and Proteome Level
por: Psatha, Konstantina, et al.
Publicado: (2023)

伴t(14;18)(q32;q21)的慢性淋巴细胞白血病八例报告并文献复习
Publicado: (2021)

Structure of a Stapled Peptide Antagonist Bound to Nutlin-Resistant Mdm2
por: Chee, Sharon Min Qi, et al.
Publicado: (2014)

MYC/BCL2 double- and MYC/BCL2/BCL6 triple-hit follicular lymphomas associated with t(8;14;18)(q24;q32;q21)
por: Takeoka, Kayo, et al.
Publicado: (2022)

Waldenstrom's macroglobulinemia-like B cell lymphoma with MYD88 L265P mutation and t(14;18)(q32;q21) involving IGH-MALT1
por: Furuta, Rie, et al.
Publicado: (2023)

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63
por: Gamble, Laura D., et al.
Publicado: (2011)

Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
por: Yee-Lin, Voon, et al.
Publicado: (2018)

Evaluation of bcl-2 protein expression and 14;18 translocation as prognostic markers in follicular lymphoma.
por: Pezzella, F., et al.
Publicado: (1992)

Apoptosis of t(14;18)-positive lymphoma cells by a Bcl-2 interacting small molecule
por: Abbott, David R., et al.
Publicado: (2009)

Biallelic BCL6 rearrangements by dual t(3;14)(q27;q32) and t(3;22)(q27;q11) translocations in diffuse large B-cell lymphoma
por: Nakamura, Yuichi, et al.
Publicado: (2022)

Pulmonary extranodal marginal zone lymphoma that presented with macroglobulinemia and marked plasmacytic cell proliferation carrying the t(14;18)(q32;q21)/MALT1-immunoglobulin heavy-chain fusion gene in pleural fluid
por: Akasaka, Takashi, et al.
Publicado: (2018)

The Pharmacodynamics of the p53-Mdm2 Targeting Drug Nutlin: The Role of Gene-Switching Noise
por: Puszynski, Krzysztof, et al.
Publicado: (2014)

Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3
por: Yang, Peipei, et al.
Publicado: (2016)

Primary Chest Wall MYC/BCL6 Double-hit Lymphoma with t(3;7)(q27;p12) and t(8;14)(q24;q32) Translocations
por: Kamachi, Kazuharu, et al.
Publicado: (2019)

Correction: The Pharmacodynamics of the p53-Mdm2 Targeting Drug Nutlin: The Role of Gene-Switching Noise
Publicado: (2015)

Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53
por: Walter, Robert F. H., et al.
Publicado: (2018)

MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines
por: Ohnstad, Hege O, et al.
Publicado: (2011)

Reduced transcriptional activity in the p53 pathway of senescent cells revealed by the MDM2 antagonist nutlin-3
por: Huang, Baoying, et al.
Publicado: (2009)

A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation
por: Valentine, Jane M, et al.
Publicado: (2011)

MDM2-p53 Interactions in Human Hepatocellular Carcinoma: What Is the Role of Nutlins and New Therapeutic Options?
por: Azer, Samy A.
Publicado: (2018)

PB2171: THE NOVEL CSN5/JAB1 INHIBITOR CSN5I-3 SUPPRESSES CELL GROWTH AND UPREGULATES GENE EXPRESSION OF TYPE-I INTERFERONS (IFN) IN ANAPLASTIC LARGE CELL LYMPHOMA (ALCL)
por: Xagoraris, I., et al.
Publicado: (2022)

mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells
por: Chen, Weina, et al.
Publicado: (2010)

Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53
por: Arya, A K, et al.
Publicado: (2010)

Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway
por: Ludwig, Michael P., et al.
Publicado: (2023)

Novel ZEB2-BCL11B Fusion Gene Identified by RNA-Sequencing in Acute Myeloid Leukemia with t(2;14)(q22;q32)
por: Torkildsen, Synne, et al.
Publicado: (2015)

Linkage to chromosome 2q32.2-q35 in families with serrated neoplasia
por: Roberts, Aedan, et al.
Publicado: (2010)

A double‐hit High‐grade B‐cell lymphoma with three‐way translocation t(3;8;14)(q27;q24;q32) involving BCL6, MYC, and IGH
por: De Paoli, Elena, et al.
Publicado: (2018)

The MDM2 ligand Nutlin-3 differentially alters expression of the immune blockade receptors PD-L1 and CD276
por: Li, Ruidong, et al.
Publicado: (2020)

Formation of a G-quadruplex at the BCL2 major breakpoint region of the t(14;18) translocation in follicular lymphoma
por: Nambiar, Mridula, et al.
Publicado: (2011)

Blocking ETV6/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemia
por: Kaindl, U, et al.
Publicado: (2014)

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells
por: Michaelis, M, et al.
Publicado: (2011)

Fibroid explants reveal a higher sensitivity against MDM2-inhibitor nutlin-3 than matching myometrium
por: Markowski, Dominique N, et al.
Publicado: (2012)

Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3
por: Pechackova, Sona, et al.
Publicado: (2016)

Rearrangement of mitochondrial pyruvate dehydrogenase subunit dihydrolipoamide dehydrogenase protein–protein interactions by the MDM2 ligand nutlin‐3
por: Way, Luke, et al.
Publicado: (2016)

Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a
por: Fontana, Maria Chiara, et al.
Publicado: (2021)

MDM2 inhibitors, nutlin-3a and navtemadelin, retain efficacy in human and mouse cancer cells cultured in hypoxia
por: Lerma Clavero, Ada, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kh2il13sudeg4eid2ofl5hj1of